First evidence that FGF23 may promote LVH came from clinical association studies in CKD patients (Gutierrez et al., 2008, 2009; Leifheit-Nestler et al., 2016), which was verified in different rodent models of experimental uremia (Faul et al., 2011; Leifheit-Nestler et al., 2017; Czaya et al., 2019). This evidence concerns the gene FGF23 and chronic kidney disease.